Mikhail Blagosklonny

Mikhail Blagosklonny
Fields Anti-Aging Medicine, Cancer
Institutions Roswell Park Cancer Institute
Education MD, PhD
Alma mater First Pavlov State Medical University of St. Peterburg

Mikhail Blagosklonny is a scientist who studies cancer and aging. In 2009, he was appointed Professor of Oncology at the Roswell Park Cancer Institute in New York.[1]

Career

Blagosklonny earned both his M.D. (Medical Doctorate) in internal medicine and his PhD in experimental medicine & cardiology from the Russian medical university the First Pavlov State Medical University of St. Peterburg.[1]

Blagosklonny was appointed Associate Professor of Medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a Senior Scientist at Ordway Research Institute, Albany, New York. Blagosklonny held this position until 2009 when he was appointed Professor of Oncology at Roswell Park Cancer Institute.[1]

Blogosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs and.[1]

Editorial Positions

Editor-in-Chief & Co-Founding editor: Aging;[2] which as of 2013 was the second highest ranked journal in the field of aging research [3]

Editor-in-Chief: Cell Cycle.[4]

Editor-in-Chief: Oncotarget[5]

Founding member: 700forscience;[6] a group of commercialization experts helping to create a grassroots support system, for innovative biotechnology projects.[7]

Selected publications

References

  1. 1 2 3 4 Roswell Park Cancer Center Mikhail Blagosklonny profile Page accessed May 16, 2015
  2. "Aging Editorial Board". Retrieved 12 Aug 2014.
  3. "SCImago Aging Field Journal ranks". Retrieved May 16, 2015.
  4. "Cell Cycle Editorial Board". Retrieved May 16, 2015.
  5. "Oncotarget Editorial Board". Retrieved May 16, 2015.
  6. "700forscience founder".
  7. "700 for science about".
This article is issued from Wikipedia - version of the Sunday, September 13, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.